Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 13/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 6/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | ITK | Q08881 | 2/20 | 0.42 |
| ▸ | MERTK | Q12866 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486367 | 0.96 | MAP3K5 (0.53) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| Hydrochloric Acid SCHEMBL3486368 | 0.95 | MAP3K5 (0.53) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| SCHEMBL3486468 | 0.82 | MAP3K5 (0.52) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| Hydrochloric Acid SCHEMBL3486380 | 0.81 | MAP3K5 (0.51) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| SCHEMBL3486280 | 0.81 | MAP3K5 (0.67) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| Formic Acid SCHEMBL3485813 | 0.79 | MAP3K5 (0.50) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| SCHEMBL3486597 | 0.79 | MAP3K5 (0.53) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| Hydrochloric Acid SCHEMBL3486957 | 0.78 | MAP3K5 (0.53) | MAP3K5CSNK1DCSNK1ERETCDK2 | |
| Formic Acid SCHEMBL3485941 | 0.78 | MAP3K5 (0.48) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL3486372 | 0.77 | MAP3K5 (0.72) | MAP3K5RETCDK2GSK3BITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | MAP3K5 42/4885CSNK1D 666/4885CSNK1E 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.